论文部分内容阅读
左旋咪唑是一种人工合成的、具有调节免疫机能的口服剂,相对无毒。作者将未经治疗的60例急性非淋巴细胞白血病(ANLL)患者作为研究对象。所有患者均用同一化疗方案,主要用柔红霉素和阿糖胞苷作为诱导和强化治疗。第一组30例单用化疗,第二组30例除化疗外,加用左旋咪唑。诱导治疗开始1周后,按45mg/m~2开始口服,每日2次,每周连用3天,直至复发。比较2组的缓解率、缓解期、生存期及第二次缓解。 60例中最后可供评价的只有56例。单纯化疗组完全缓解率为62%(18/29),左旋咪唑组者为59%(16/27)。单纯化疗组达缓解所需时间平均为36.5天(范围在24-91天),左旋咪唑组平均为32天(范围在22-
Levamisole is a synthetic, oral agent that regulates immune function and is relatively non-toxic. The authors studied 60 untreated acute lymphoblastic leukemia (ANLL) patients. All patients used the same chemotherapy regimen, mainly daunorubicin and cytarabine as induction and intensive treatment. The first group of 30 patients received chemotherapy alone. The second group of 30 patients received levamisole in addition to chemotherapy. One week after induction therapy, oral administration was started at 45 mg/m 2 twice daily for 3 days until recurrence. The remission rate, remission period, survival period, and second remission were compared in the 2 groups. Of the 60 cases, only 56 were available for evaluation. The complete remission rate was 62% (18/29) in the chemotherapy alone group and 59% (16/27) in the levamisole group. The time required for remission in the chemotherapy-only group was an average of 36.5 days (range 24-91 days), and that for the levamisole group was 32 days (range 22-